Pandemic Influenza Preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits Delivered by Paula Barbosa, Manager, Vaccines Policy Pandemic influenza is a top global health priority for WHO in 2019. Seasonal influenza is also a significant public health concern, and the associated infrastructure required to support seasonal programs also enhances pandemic preparedness. The timely development and production of...
Read moreDelivered by Vanessa Peberdy, Manager, Global Health Policy, IFPMA IFPMA welcomes the Political Declaration of the third High Level Meeting on NCDs, held in September last year. We were encouraged by the high political attention given to the meeting and the adoption of 14 new commitments by Heads of States and Government, as well as...
Read moreThis oped was first published on The Nation on 30 January 2019. It’s clear we live in a global village when England striker Jamie Vardy of Thai-owned Leicester City[1] praises Thai rocker Toon Bodyslam’s 2,215 km charity run over 55 days in 2017 that raised Bt1.37 billion/$35 million for 11 public hospitals and says: “Your actions...
Read moreDelivered by Sara Amini, Senior Manager, Social and Economic Policy, IFPMA IFPMA and its members are fully committed to partnering with governments and the WHO to improve access to and affordability of treatments to fight cancer. We are concerned that the Technical Report has been developed without adequate consultations with key stakeholders, including industry, as...
Read moreDelivered by Grega Kumer, Head of DG Office & Legal Issues, IFPMA The access roadmap offers an opportunity for WHO to address immediate patient needs worldwide. We welcome that WHO has put emphasis on areas where it has a unique mandate and that are covered by the Thirteenth GPW, such as those under “ensuring the...
Read more“This blog was first published in Pharma Exec on 23 January 2019″ As a Brit living and working abroad, I am transfixed by what I’m witnessing together with many others, as the fallout from the June 2016 referendum continues to wrack the UK political landscape. As scenarios, timelines, policy implications (including for the pharmaceutical...
Read moreGeneva, 23 January 2019: IFPMA, the global R&D biopharmaceutical industry association, welcomes the 11th G-FINDER report[i] which tracks public, private and philanthropic investment into product R&D for neglected diseases, which predominantly affect the developing countries. As with previous years, the report shows Bio-pharmaceutical industry investment as the third largest funder, after the USA’s National Institutes...
Read moreThis oped was published first on IP Watch on 16 January 2019 The views expressed in this article are solely those of the authors and are not associated with Intellectual Property Watch. IP-Watch expressly disclaims and refuses any responsibility or liability for the content, style or form of any posts made to this forum, which...
Read moreFor millions of people worldwide out-of-pocket health expenses translate to out-of-reach opportunities for the future. Children miss out on essential immunizations, women die giving birth in unsafe environments, and people are at risk of going blind or having a stroke before they realize they are not properly controlling their diabetes. To quote Dr Tedros Adhanom...
Read moreThe new Code of Practice in place from 1 January 2019, imposes a complete ban on gifts and promotional aids Industry moves beyond compliance and reaffirms its commitment to ensuring an ethical framework as a way to increase integrity and trust Industry presents new Code to patients and healthcare professionals 10 January 2019, Geneva –...
Read moreThe new IFPMA Code of Practice will come into effect on 1st January 2019.This video and supporting slide-deck summarizes the key changes between the new IFPMA Code of Practice 2019 and its 2012 predecessor, and discusses certain implications of these revisions for our members.
Read moreThis oped was first published on IAPO Newsletter on 17 December 2018. An efficient healthcare system depends on mutual trust between patients, healthcare professionals, regulators and pharmaceutical companies – but how should that translate concretely into the day to day reality of whether a healthcare professional should be given a subscription to a journal or...
Read more